Clinical Trials Logo

Cystic Fibrosis clinical trials

View clinical trials related to Cystic Fibrosis.

Filter by:

NCT ID: NCT00004747 Completed - Cystic Fibrosis Clinical Trials

Phase II Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Mucoid Exopolysaccharide Pseudomonas Aeruginosa Immune Globulin for Cystic Fibrosis

Start date: July 1995
Phase: Phase 2
Study type: Interventional

OBJECTIVES: I. Assess the efficacy of monthly intravenous mucoid exopolysaccharide Pseudomonas aeruginosa immune globulin (MEP IGIV) given over 1 year in reducing the frequency of acute pulmonary exacerbation in patients with cystic fibrosis, mild to moderate pulmonary disease, and mucoid P. aeruginosa colonization. II. Assess the effect of MEP IGIV on FEV1, sputum density of mucoid P. aeruginosa, and the quality of life in these patients. III. Assess the safety of monthly MEP IGIV. IV. Assess population-based MEP IGIV pharmacokinetics during chronic therapy.

NCT ID: NCT00004705 Completed - Cystic Fibrosis Clinical Trials

Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis

Start date: September 1996
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Determine the stability of uridine triphosphate (UTP) and examine the metabolism of exogenous nucleotides on airway epithelial surfaces in patients with cystic fibrosis. II. Determine the acute safety and efficacy of aerosolized UTP in children with cystic fibrosis.

NCT ID: NCT00004533 Completed - Cystic Fibrosis Clinical Trials

Phase I Randomized Study of Adeno-Associated Virus-CFTR Vector in Patients With Cystic Fibrosis

Start date: August 1999
Phase: Phase 1
Study type: Interventional

OBJECTIVES: I. Determine the maximum tolerated dose of recombinant adeno-associated virus-CFTR vector in patients with cystic fibrosis. II. Assess the safety of this gene therapy in these patients. III. Assess the in vivo gene transfer of this vector in these patients. IV. Assess the CFTR gene expression and physiologic activity following gene transfer in these patients. V. Assess the clinical impact of CFTR gene expression following gene transfer in these patients. VI. Monitor patient immune response directed against CFTR or vector components following vector administration.

NCT ID: NCT00004489 Completed - Cystic Fibrosis Clinical Trials

Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis

Start date: October 1998
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Determine the bioavailability and biologic effect of alendronate on bone metabolism in patients with cystic fibrosis. II. Assess the safety and efficacy of this treatment regimen in improving osteoporosis in this patient population.

NCT ID: NCT00004471 Completed - Cystic Fibrosis Clinical Trials

Phase I Pilot Study of Gene Therapy for Cystic Fibrosis Using Cationic Liposome Mediated Gene Transfer

Start date: August 1995
Phase: Phase 1
Study type: Interventional

OBJECTIVES: Determine whether copies of the cystic fibrosis gene (pGT-1) can be delivered to the cells lining the nose of cystic fibrosis patients using cationic liposome (DMRIE/DOPE) mediated gene transfer.

NCT ID: NCT00004441 Completed - Cystic Fibrosis Clinical Trials

Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis

Start date: September 1997
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Determine the optimum dose of tauroursodeoxycholic acid (TUDCA) required to achieve maximal bioavailability for patients with cystic fibrosis-associated liver disease. II. Compare optimized doses of TUDCA with ursodiol (ursodeoxycholic acid; UDCA) for effects on biliary bile acid composition and metabolism, serum biochemistries, fat absorption, and fat-soluble vitamin status in these patients.

NCT ID: NCT00004440 Completed - Cystic Fibrosis Clinical Trials

Study of Ibuprofen to Preserve Lung Function in Patients With Cystic Fibrosis

Start date: August 1996
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Determine the effect of different doses of ibuprofen on neutrophil (polymorphonuclear leukocyte; PMN) delivery to a mucosal surface (the oral mucosa) in patients with cystic fibrosis and healthy controls. II. Determine the duration of effect (and possible rebound effect) of ibuprofen on PMN delivery to a mucosal surface in these patients.

NCT ID: NCT00004428 Completed - Cystic Fibrosis Clinical Trials

Phase I Randomized Study of CPX for the Treatment of Adult Patients With Mild Cystic Fibrosis

Start date: September 1997
Phase: Phase 1
Study type: Interventional

OBJECTIVES: I. Evaluate the safety of ascending doses of CPX administered to adult patients with mild cystic fibrosis. II. Evaluate the pharmacokinetics of ascending doses of CPX in this patient population.

NCT ID: NCT00004296 Completed - Cystic Fibrosis Clinical Trials

Multicenter Study of Nontuberculous Mycobacteria in Cystic Fibrosis Patients

Start date: September 1995
Phase: N/A
Study type: Observational

OBJECTIVES: I. Determine the prevalence of nontuberculous mycobacteria in sputum cultures from patients with cystic fibrosis. II. Compare the clinical course of patients with negative versus positive cultures.

NCT ID: NCT00004287 Completed - Cystic Fibrosis Clinical Trials

Phase I Study of the Third Generation Adenovirus H5.001CBCFTR in Patients With Cystic Fibrosis

Start date: November 1995
Phase: Phase 1
Study type: Interventional

OBJECTIVES: I. Assess the safety and feasibility of gene transfer with the third generation adenovirus H5.001CBCFTR in patients with cystic fibrosis.